Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

News & Analysis

China biotech company and industry news and analysis...

Week in Review: Kumquat Signs $2 Billion US-China Deal with Lilly for Novel Immune Drugs

Neukio Bio of Shanghai Raises $40 Million for Universal CAR-T Therapies

Lupeng Pharma Closes $35 Million Pre-B Funding for Novel Drugs

I-Mab to Start US Phase I Trial of Immunotherapy for Alzheimer's

Kumquat Announces $2 Billion Deal to Develop Small Molecule IO Drugs with Lilly

Upcoming event
Shanghai and Digital
May 10-14, 2021
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
The Ritz-Carlton Shanghai Pudong
March 23-25, 2021